Whole genome sequencing for breast cancer
Part of Cancer, Skin clinical trials.
This trial uses whole genome sequencing, a test that reads the complete set of your DNA, to study breast cancer tissue. This may help doctors learn more about the disease and find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You must have been diagnosed with breast cancer, or doctors suspect it based on imaging tests.
- You must be able to provide a tissue sample (from a biopsy or surgery).
- You must agree to have your genetic information studied.
- You must sign consent forms for the study and for using your tissue.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special DNA and RNA testing tools to better understand differences between breast cancer tumors in Taiwanese patients. It may help doctors choose more personalized treatment approaches by learning how tumors vary.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
This is an observational study that collects real-world information from adults with lung cancer or breast cancer. It may help doctors better understand how people do over time and how treatments and outcomes relate to details from your medical record and tests.
This trial helps doctors study and analyze cancer- or precancer-related DNA information. If you’re 18 or older and can consent, your results may help researchers understand the biology of your condition and guide future care.
This study looks at stored tumor samples to understand why some people respond much better or much worse than expected. The goal is to learn what the tumor’s genes might be telling doctors about response to treatment.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.